ABAgnes Brandtmüller

Agnes Brandtmüller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Agnes Brandtmüller has a total of 27 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Real-world utilization of pembrolizumab dosing schedules in Belgium: a multi-center retrospective study using a common data model and natural language processing

    by Annelies Verbiest, Hans Prenen, Annelies Janssens, Christof Vulsteke, Danielle Delombaerde, Laura Tack, Philip R Debruyne, Iege Bassez, Clara L Oeste, Agnes Brandtmüller, et al.

    Aim: Pembrolizumab's six-week extended dosing (ED), approved as an alternative to the standard three-week schedule (SD), offers flexibility in treatment plans. Materials & methods: In this retrospective study across four Belgian hospitals, we described real-world pembrolizumab utilization using a pipeline that processed unstructured data with natural language processing (NLP) and mapped both structured and unstructured data to an OMOP-CDM database. Physicians and data analysts collaboratively developed the project-specific data dictionary and performed validation. Results: A total of 303 patients were included, 56% with non-small cell lung cancer (NSCLC). Most patients (72%) received monotherapy, with 89% starting on SD. For NSCLC first-line monotherapy, the median time on treatment (rwTOT) was 106 days in the ‘SD only’ cohort and 666 days in the ‘SD to ED’ cohort, while the median time to next treatment (rwTTNT) was 280 days for ‘SD only’ (median rwTTNT not reached for ‘SD to ED’). Dosing cohort distributions showed that 74% of patients in the ‘SD to ED’ group had NSCLC, compared with 77% with urothelial cancer in the ‘ED only’ group. The mean (StdDev) gap between administrations was 23 (7) days for SD and 43 (5) days for ED. Most patients receiving ED did so after starting on SD, and all ED initiators stayed on ED. Dosing patterns remained stable pre- and during COVID-19. Conclusion: This study describes real-world pembrolizumab dosing patterns across four Belgian hospitals and illustrates how integrating NLP and structured data within an OMOP-CDM framework can support such analyses. Patients switching from SD to ED showed longer rwTOT and rwTTNT than those on SD alone, though potential immortal time bias requires caution in interpretation.

  • Open Access

    Economic value of lost productivity attributable to premature cancer mortality and morbidity across Europe

    by Agnes Brandtmüller, Anne Meiwald, Peter Toth, Chamath Perera, Aimee Fox

    Cancer imposes a substantial clinical and economic burden across Europe. This analysis estimated the lost productivity cost of the five cancer types with the highest premature mortality and five cancer types with the highest morbidity burden across 28 European countries in 2022. Data on cancer deaths, years of life lost (YLL), and years of life lived with disability (YLD) were sourced from the Institute for Health Metrics and Evaluation Global Burden of Disease database. Country- and sex-specific demographic and economic parameters were obtained. Years of productive life lost (YPLL) and present value of future lost productivity (PVFLP) were estimated for individuals dying before retirement, while the value of YLD (VYLD) quantified earnings lost due to cancer-related disability. Outcomes were adjusted for labor force participation and unemployment. Deterministic sensitivity analyses assessed the impact of variations in model inputs. In 2022, tracheal, bronchus, and lung cancer, colon and rectum cancer, breast, pancreatic, and prostate cancers accounted for 899,581 deaths, 17,274,882 YLL, 896,510 YPLL, and €30,749,064,014 PVFLP across Europe. Tracheal, bronchus, and lung cancer contributed the largest share of mortality-related productivity losses with 37.2% of deaths and 43.7% of PVFLP. Breast cancer had the highest PVFLP per death (€49,411). For morbidity, breast, prostate, colon and rectum cancer, tracheal, bronchus, and lung cancer, and non-Hodgkin lymphoma resulted in 993,648 YLD, 210,400 productive YLD (PYLD), and €9,087,096,712 VYLD. Germany, France, and United Kingdom were the largest contributors to both mortality and morbidity burdens. Sensitivity analyses indicated that retirement age was the key driver of results. Cancer continues to exert a considerable productivity burden across Europe with substantial variation between countries. These findings highlight the need for equitable cancer prevention, early diagnosis, and timely access to treatment to reduce both health and economic disparities across Europe.

  • Open Access

    Sex differences in the impact of lower respiratory tract infections on older adults’ health trajectories: a population-based cohort study

    by Ahmad Abbadi, Giorgi Beridze, Eleana Tsoumani, Agnes Brandtmüller, Merle K Hendel, Stina Salomonsson, Amaia Calderón-Larrañaga, Davide L. Vetrano

    Background: Lower respiratory tract infections (LRTIs) are a major global health concern, particularly among older adults, who have an increased risk of poorer health outcomes that persist beyond the acute infectious episode. We aimed to investigate the mid-term (up to 7 years) and long-term (up to 12 years) effects of LRTIs on the objective health status trajectories of older adults, while also considering potential sex differences. Methods: Cohort data of adults aged ≥ 60 years from the Swedish National study of Aging and Care in Kungsholmen (SNAC-K) collected between 2001 and 2016 was analyzed. Information on LRTIs was obtained from the Swedish National Patient Register, and objective health status was assessed using the Health Assessment Tool (HAT) which incorporates indicators of mild and severe disability, cognitive and physical functioning, and multimorbidity. The LRTI-exposed and -unexposed participants were matched using propensity score matching based on an expansive list of potential confounders. Mixed linear models were used to analyze the association between LRTIs and changes in HAT scores. Results: The study included 2796 participants, 567 of whom were diagnosed with a LRTI. LRTIs were independently associated with an excess annual decline of 0.060 (95% CI: -0.107, -0.013) in the HAT score over a 7-year period. The associations were stronger among males, who experienced an excess annual decline of 0.108 (95% CI: -0.177, -0.039) in up to 7-years follow-up, and 0.097 (95% CI: -0.173, -0.021) in up to 12-years follow-up. The associations were not statistically significant among females in either follow-up period. Conclusion: LRTIs, even years after the acute infectious period, seem to have a prolonged negative effect on the health of older adults, particularly among males. Preventative public health measures aimed at decreasing LRTI cases among older adults could help in preserving good health and functioning in old age.


  • Open Access

    Impact of lower-respiratory tract infections on healthcare utilization and mortality in older adults: a Swedish population-based cohort study

    by Ahmad Abbadi, Susanna Gentili, Eleana Tsoumani, Agnes Brandtmüller, Merle K. Hendel, Stina Salomonsson, Amaia Calderón-Larrañaga, Davide L. Vetrano

    Background: Lower respiratory tract infections (LRTIs) have an immediate significant impact on morbidity and mortality among older adults. However, the impact following the infectious period of LRTI remains understudied. We aimed to assess the short- to long-term impact of LRTIs on hospitalization, mortality, and healthcare utilization in older adults. Methods: Data from the Swedish National Study of Aging and Care in Kungsholmen (SNAC-K) was analyzed, with data from 2001 to 2019 for mortality and 2001–2016 for healthcare utilization. LRTI-exposed participants were identified and matched with LRTI-nonexposed based on sociodemographics, lifestyle factors, and functional and clinical characteristics. Statistical models evaluated post-LRTI hospitalization risk, days of inpatient hospital admissions, healthcare visits, and mortality. Results: 567 LRTIs-exposed participants during the study period and were matched with 1.701 unexposed individuals. LRTI-exposed individuals exhibited increased risk of hospitalization at 1-year (HR 2.14, CI 1.74, 2.63), 3-years (HR 1.74, CI 1.46, 2.07), and 5-years (HR 1.59, CI 1.33, 1.89). They also experienced longer post-LRTI hospital stays (IRR 1.40, CI 1.18, 1.66), more healthcare visits (IRR 1.47, CI 1.26, 1.71), specialist-care visits (IRR 1.46, CI 1.24, 1.73), and hospital admissions (IRR 1.57, CI 1.34, 1.83) compared to nonexposed participants over 16-years of potential follow-up. Additionally, the 19-year risk of mortality was higher among LRTI-exposed participants (HR 1.45, CI 1.24, 1.70). Men exhibited stronger associations with these risks compared to women. Conclusions: LRTIs pose both short- and long-term risks for older adults, including increased risks of mortality, hospitalization, and healthcare visits that transpire beyond the acute infection period, although these effects diminish over time. Men exhibit higher risks across these outcomes compared to women. Given the potential preventability of LRTIs, further public health measures to mitigate infection risk are warranted.


  • Open Access

    Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature

    by Stuti Arya, Nicholas Norton, Puneet Kaushik, Agnes Brandtmüller, Eleana Tsoumani

    Despite widespread use of pneumococcal vaccines throughout Europe, the burden of pneumococcal disease (PD) in adults is considerable. To mitigate this burden, National Immunization Technical Advisory Groups (NITAGs) and Health Technology Assessment (HTA) agencies assess the value of different vaccine schedules for protecting against PD. The aim of this review was to assess the evidence and rationales used by NITAGs/HTA agencies, when considering recent changes to National Immunization Programs (NIPs) for adults, and how identified changes affected vaccine coverage rates (VCRs). A systematic review was conducted of published literature from PubMed® and Embase®, and gray literature from HTA/NITAG websites from the last 5 y, covering 31 European countries. Evidence related to NIP recommendations, epidemiology (invasive PD, pneumonia), health economic assessments and VCRs were collected and synthesized. Eighty-four records providing data for 26 countries were identified. Of these, eight described explicit changes to NIPs for adults in seven countries. Despite data gaps, some trends were observed; first, there appears to be a convergence of NIP recommendations in many countries toward sequential vaccination, with a pneumococcal conjugate vaccine (PCV), followed by pneumococcal polysaccharide vaccine 23. Second, reducing economic or healthcare burden were common rationales for implementing changes. Third, most health economic analyses assessing higher-valency PCVs for adults found its inclusion in NIPs cost-effective. Finally, higher coverage rates were seen in most cases where countries had expanded their NIPs to cover at-risk populations. The findings can encourage agencies to improve surveillance systems and work to reach the NIP's target populations more effectively.